Gary L. Johnson, Ph.D. - Publications

Affiliations: 
Pharmacology University of Colorado, Boulder, Boulder, CO, United States 
Website:
http://www.med.unc.edu/pharm/people/primaryfaculty/gary-l-johnson

121 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL, Kissil JL. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget. PMID 27363027 DOI: 10.18632/oncotarget.10248  1
2016 Miller SM, Goulet DR, Johnson GL. Targeting the breast cancer kinome. Journal of Cellular Physiology. PMID 27186656 DOI: 10.1002/jcp.25427  1
2015 Ahmad S, Johnson GL, Scott JE. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochemical and Biophysical Research Communications. PMID 26056008 DOI: 10.1016/j.bbrc.2015.06.029  1
2015 Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, ... ... Johnson GL, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/j.celrep.2015.03.037  1
2014 Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 86: 121-5. PMID 25257766 DOI: 10.1016/j.lungcan.2014.09.005  1
2014 Zawistowski JS, Graves LM, Johnson GL. Assessing adaptation of the cancer kinome in response to targeted therapies. Biochemical Society Transactions. 42: 765-9. PMID 25109955 DOI: 10.1042/BST20130274  1
2014 Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2516-22. PMID 24664307 DOI: 10.1158/1078-0432.CCR-13-1081  1
2014 Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW. An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Molecular & Cellular Proteomics : McP. 13: 1184-97. PMID 24556848 DOI: 10.1074/mcp.M113.037374  1
2014 Stuhlmiller TJ, Earp HS, Johnson GL. Adaptive reprogramming of the breast cancer kinome. Clinical Pharmacology and Therapeutics. 95: 413-5. PMID 24413269 DOI: 10.1038/clpt.2014.8  1
2013 Pham TT, Angus SP, Johnson GL. MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & Cancer. 4: 419-26. PMID 24386504 DOI: 10.1177/1947601913513950  1
2013 Wu C, Haynes EM, Asokan SB, Simon JM, Sharpless NE, Baldwin AS, Davis IJ, Johnson GL, Bear JE. Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. The Journal of Cell Biology. 203: 907-16. PMID 24344184 DOI: 10.1083/jcb.201306032  1
2013 Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Johnson GL, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.MCT-13-0040  1
2013 Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, ... Johnson GL, et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. Plos One. 8: e66755. PMID 23826126 DOI: 10.1371/journal.pone.0066755  1
2013 Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/MCB.01443-12  1
2013 Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Molecular and Cellular Biology. 33: 2260-74. PMID 23530058 DOI: 10.1128/MCB.00269-13  1
2013 Dillon PJ, Gregory SM, Tamburro K, Sanders MK, Johnson GL, Raab-Traub N, Dittmer DP, Damania B. Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host & Microbe. 13: 204-14. PMID 23414760 DOI: 10.1016/j.chom.2012.12.005  1
2013 Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. The Biochemical Journal. 450: 1-8. PMID 23343193 DOI: 10.1042/BJ20121456  1
2013 Ahmad S, Hughes MA, Johnson GL, Scott JE. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. Journal of Biomolecular Screening. 18: 388-99. PMID 23134735 DOI: 10.1177/1087057112466430  1
2013 Richardson BT, Dibble CF, Borikova AL, Johnson GL. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biological Chemistry. 394: 35-42. PMID 23096573 DOI: 10.1515/hsz-2012-0243  1
2012 Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.CCR-12-0563  1
2012 Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Johnson GL, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/j.cell.2012.02.053  1
2012 Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS, Graves LM, Gomez SM, Johnson GL. Defining the expressed breast cancer kinome. Cell Research. 22: 620-3. PMID 22310242 DOI: 10.1038/cr.2012.25  1
2012 Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL. Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. Oncogene. 31: 3889-900. PMID 22139075 DOI: 10.1038/onc.2011.544  1
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, MacHius M, Johnson GL, et al. Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia Acs Medicinal Chemistry Letters. 3: 129-134. DOI: 10.1021/ml200239k  1
2011 Jordan NV, Johnson GL, Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (Georgetown, Tex.). 10: 2865-73. PMID 21862874 DOI: 10.4161/cc.10.17.17188  1
2011 Huang W, Umbach DM, Vincent Jordan N, Abell AN, Johnson GL, Li L. Efficiently identifying genome-wide changes with next-generation sequencing data. Nucleic Acids Research. 39: e130. PMID 21803788 DOI: 10.1093/nar/gkr592  1
2011 Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 8: 525-37. PMID 21549327 DOI: 10.1016/j.stem.2011.03.008  1
2011 Johnson GL. Defining MAPK interactomes. Acs Chemical Biology. 6: 18-20. PMID 21128644 DOI: 10.1021/cb100384z  1
2010 Nakamura K, Johnson GL. Activity assays for extracellular signal-regulated kinase 5. Methods in Molecular Biology (Clifton, N.J.). 661: 91-106. PMID 20811978 DOI: 10.1007/978-1-60761-795-2_5  1
2010 Konhilas JP, Boucek DM, Horn TR, Johnson GL, Leinwand LA. The role of MEKK1 in hypertrophic cardiomyopathy. International Heart Journal. 51: 277-84. PMID 20716846 DOI: JST.JSTAGE/ihj/51.277  1
2010 Dibble CF, Horst JA, Malone MH, Park K, Temple B, Cheeseman H, Barbaro JR, Johnson GL, Bencharit S. Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. Plos One. 5: e11740. PMID 20668527 DOI: 10.1371/journal.pone.0011740  1
2010 Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. The Journal of Biological Chemistry. 285: 11760-4. PMID 20181950 DOI: 10.1074/jbc.C109.097220  1
2010 Nakamura K, Kimple AJ, Siderovski DP, Johnson GL. PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. The Journal of Biological Chemistry. 285: 2077-89. PMID 19903815 DOI: 10.1074/jbc.M109.065102  1
2009 Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G. Coordination of Rho GTPase activities during cell protrusion. Nature. 461: 99-103. PMID 19693013 DOI: 10.1038/nature08242  1
2009 Johnson GL, Gomez SM. Sequence patches on MAPK surfaces define protein-protein interactions. Genome Biology. 10: 222. PMID 19519955 DOI: 10.1186/gb-2009-10-6-222  1
2009 Frye SV, Johnson GL. Inhibitors paradoxically prime kinases. Nature Chemical Biology. 5: 448-9. PMID 19465930 DOI: 10.1038/nchembio.f.11  1
2009 Crose LE, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. The Journal of Biological Chemistry. 284: 13301-5. PMID 19318350 DOI: 10.1074/jbc.C900009200  1
2009 Abell AN, Granger DA, Johnson NL, Vincent-Jordan N, Dibble CF, Johnson GL. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Molecular and Cellular Biology. 29: 2748-61. PMID 19289495 DOI: 10.1128/MCB.01391-08  1
2009 Xie L, Jing L, Yu Y, Nakamura K, Parker CE, Johnson GL, Chen X. In vivo profiling endogenous interactions with knock-out in mammalian cells. Analytical Chemistry. 81: 1411-7. PMID 19199569 DOI: 10.1021/ac802161d  1
2008 Wu Y, Johnson GL, Gomez SM. Data-driven modeling of cellular stimulation, signaling and output response in RAW 264.7 cells. Journal of Molecular Signaling. 3: 11. PMID 18498628 DOI: 10.1186/1750-2187-3-11  1
2008 Nakamura K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh LA, Johnson GL, Scott JE. Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization. Journal of Biomolecular Screening. 13: 396-405. PMID 18480472 DOI: 10.1177/1087057108318281  1
2008 Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 27: 4434-45. PMID 18372913 DOI: 10.1038/onc.2008.84  1
2008 Mendoza H, Campbell DG, Burness K, Hastie J, Ronkina N, Shim JH, Arthur JS, Davis RJ, Gaestel M, Johnson GL, Ghosh S, Cohen P. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. The Biochemical Journal. 409: 711-22. PMID 18021073 DOI: 10.1042/BJ20071149  1
2008 Stalheim L, Johnson GL. MAPK kinase kinase regulation of SAPK/JNK pathways Topics in Current Genetics. 20: 1-15. DOI: 10.1007/4735_2007_0238  1
2007 Hilder TL, Malone MH, Bencharit S, Colicelli J, Haystead TA, Johnson GL, Wu CC. Proteomic identification of the cerebral cavernous malformation signaling complex. Journal of Proteome Research. 6: 4343-55. PMID 17900104 DOI: 10.1021/pr0704276  1
2007 Hilder TL, Malone MH, Johnson GL. Hyperosmotic induction of mitogen-activated protein kinase scaffolding. Methods in Enzymology. 428: 297-312. PMID 17875425 DOI: 10.1016/S0076-6879(07)28017-6  1
2007 Winter-Vann AM, Johnson GL. Integrated activation of MAP3Ks balances cell fate in response to stress. Journal of Cellular Biochemistry. 102: 848-58. PMID 17786929 DOI: 10.1002/jcb.21522  1
2007 Abell AN, Granger DA, Johnson GL. MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta. The Journal of Biological Chemistry. 282: 30476-84. PMID 17726008 DOI: 10.1074/jbc.M705783200  1
2007 Malone MH, Sciaky N, Stalheim L, Hahn KM, Linney E, Johnson GL. Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae. Bmc Biotechnology. 7: 40. PMID 17623073 DOI: 10.1186/1472-6750-7-40  1
2007 Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 26: 3159-71. PMID 17496913 DOI: 10.1038/sj.onc.1210409  1
2007 Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene. 26: 3097-9. PMID 17496908 DOI: 10.1038/sj.onc.1210395  1
2007 Nakamura K, Johnson GL. Noncanonical function of MEKK2 and MEK5 PB1 domains for coordinated extracellular signal-regulated kinase 5 and c-Jun N-terminal kinase signaling. Molecular and Cellular Biology. 27: 4566-77. PMID 17452462 DOI: 10.1128/MCB.00125-07  1
2007 Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochimica Et Biophysica Acta. 1773: 1341-8. PMID 17306896 DOI: 10.1016/j.bbamcr.2006.12.009  1
2007 Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z. MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Molecular and Cellular Biology. 27: 510-7. PMID 17101801 DOI: 10.1128/MCB.01355-06  1
2007 Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26: 2791-8. PMID 17057734 DOI: 10.1038/sj.onc.1210072  1
2007 Dhanasekaran DN, Johnson GL. Guest editors Oncogene. 26: 3095-3096. DOI: 10.1038/sj.onc.1210393  1
2006 Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, ... Johnson GL, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene. 25: 6092-100. PMID 16652142 DOI: 10.1038/sj.onc.1209633  1
2006 Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene. 25: 4998-5010. PMID 16568086 DOI: 10.1038/sj.onc.1209507  1
2006 Nakamura K, Uhlik MT, Johnson NL, Hahn KM, Johnson GL. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Molecular and Cellular Biology. 26: 2065-79. PMID 16507987 DOI: 10.1128/MCB.26.6.2065-2079.2006  1
2005 Lapadat R, Debiasi RL, Johnson GL, Tyler KL, Shah I. Genes Induced by Reovirus Infection Have a Distinct Modular Cis-Regulatory Architecture. Current Genomics. 6: 501-513. PMID 23335855 DOI: 10.2174/138920205775067675  1
2005 Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. The American Journal of Pathology. 167: 1763-75. PMID 16314486 DOI: 10.1016/S0002-9440(10)61257-6  1
2005 Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Molecular and Cellular Biology. 25: 8948-59. PMID 16199873 DOI: 10.1128/MCB.25.20.8948-8959.2005  1
2005 Abell AN, Johnson GL. MEKK4 is an effector of the embryonic TRAF4 for JNK activation. The Journal of Biological Chemistry. 280: 35793-6. PMID 16157600 DOI: 10.1074/jbc.C500260200  1
2005 Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Human Molecular Genetics. 14: 2521-31. PMID 16037064 DOI: 10.1093/hmg/ddi256  1
2005 Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Current Opinion in Chemical Biology. 9: 325-31. PMID 15939336 DOI: 10.1016/j.cbpa.2005.04.004  1
2005 Li Y, Minamino T, Tsukamoto O, Yujiri T, Shintani Y, Okada K, Nagamachi Y, Fujita M, Hirata A, Sanada S, Asanuma H, Takashima S, Hori M, Johnson GL, Kitakaze M. Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model. Circulation. 111: 1672-8. PMID 15795331 DOI: 10.1161/01.CIR.0000160350.20810.0F  1
2005 Uhlik MT, Temple B, Bencharit S, Kimple AJ, Siderovski DP, Johnson GL. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. Journal of Molecular Biology. 345: 1-20. PMID 15567406 DOI: 10.1016/j.jmb.2004.10.038  1
2005 Cuevas BD, Uhlik MT, Garrington TP, Johnson GL. MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability. Oncogene. 24: 801-9. PMID 15558021 DOI: 10.1038/sj.onc.1208239  1
2004 Uhlik MT, Abell AN, Cuevas BD, Nakamura K, Johnson GL. Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 82: 658-63. PMID 15674433 DOI: 10.1139/o04-114  1
2004 Clarke P, Meintzer SM, Wang Y, Moffitt LA, Richardson-Burns SM, Johnson GL, Tyler KL. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. Journal of Virology. 78: 13132-8. PMID 15542665 DOI: 10.1128/JVI.78.23.13132-13138.2004  1
2004 Anderson MS, Knall C, Thurman G, Mann D, Cusack N, Johnson GL, Ambruso DR. CP-64131, an aminobenzazepine with cytokine-like properties, stimulates human neutrophil functions through the p38-MAPK pathway. Journal of Leukocyte Biology. 76: 477-83. PMID 15155776 DOI: 10.1189/jlb.0903422  1
2004 Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL, Garrington TP. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. Journal of Cellular Physiology. 199: 140-8. PMID 14978743 DOI: 10.1002/jcp.10457  1
2004 Abell AN, DeCathelineau AM, Weed SA, Ambruso DR, Riches DW, Johnson GL. Rac2D57N, a dominant inhibitory Rac2 mutant that inhibits p38 kinase signaling and prevents surface ruffling in bone-marrow-derived macrophages. Journal of Cell Science. 117: 243-55. PMID 14676277 DOI: 10.1242/jcs.00853  1
2004 Lieber JG, Webb S, Suratt BT, Young SK, Johnson GL, Keller GM, Worthen GS. The in vitro production and characterization of neutrophils from embryonic stem cells. Blood. 103: 852-9. PMID 14525782 DOI: 10.1182/blood-2003-04-1030  1
2003 Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, Horne EA, Dell'Acqua ML, Johnson GL. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nature Cell Biology. 5: 1104-10. PMID 14634666 DOI: 10.1038/ncb1071  1
2003 Wei X, Sun W, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington T, Dakhama A, Lucas J, Johnson GL, Gelfand EW. MEF2C regulates c-Jun but not TNF-alpha gene expression in stimulated mast cells. European Journal of Immunology. 33: 2903-9. PMID 14515274 DOI: 10.1002/eji.200324127  1
2003 Nakamura K, Johnson GL. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. The Journal of Biological Chemistry. 278: 36989-92. PMID 12912994 DOI: 10.1074/jbc.C300313200  1
2003 DeBiasi RL, Clarke P, Meintzer S, Jotte R, Kleinschmidt-Demasters BK, Johnson GL, Tyler KL. Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis. Journal of Virology. 77: 8934-47. PMID 12885910 DOI: 10.1128/JVI.77.16.8934-8947.2003  1
2003 Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson NL, Kesavan K, Ware M, Jones PL, Weed SA, DeBiasi RL, Oka Y, Tyler KL, Johnson GL. MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. The Embo Journal. 22: 3346-55. PMID 12839996 DOI: 10.1093/emboj/cdg322  1
2003 Sun W, Wei X, Kesavan K, Garrington TP, Fan R, Mei J, Anderson SM, Gelfand EW, Johnson GL. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Molecular and Cellular Biology. 23: 2298-308. PMID 12640115 DOI: 10.1128/MCB.23.7.2298-2308.2003  1
2003 Witowsky J, Abell A, Johnson NL, Johnson GL, Cuevas BD. MEKK1 is required for inducible urokinase-type plasminogen activator expression. The Journal of Biological Chemistry. 278: 5941-6. PMID 12493778 DOI: 10.1074/jbc.M212363200  1
2003 Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. The Journal of Biological Chemistry. 278: 1403-6. PMID 12456688 DOI: 10.1074/jbc.C200616200  1
2002 Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (New York, N.Y.). 298: 1911-2. PMID 12471242 DOI: 10.1126/science.1072682  1
2002 Bild AH, Mendoza FJ, Gibson EM, Huang M, Villanueva J, Garrington TP, Jove R, Johnson GL, Gibson SB. MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage. Oncogene. 21: 6649-56. PMID 12242663 DOI: 10.1038/sj.onc.1205819  1
2002 Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nature Reviews. Molecular Cell Biology. 3: 663-72. PMID 12209126 DOI: 10.1038/nrm906  1
2002 Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma Cancer Research. 62: 3971-3979. PMID 12124329  1
2002 Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. The Journal of Clinical Investigation. 110: 271-9. PMID 12122119 DOI: 10.1172/JCI14938  1
2002 Kassenbrock CK, Hunter S, Garl P, Johnson GL, Anderson SM. Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. The Journal of Biological Chemistry. 277: 24967-75. PMID 11994282 DOI: 10.1074/jbc.M201026200  1
2002 Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism Proceedings of the National Academy of Sciences of the United States of America. 99: 4608-4613. PMID 11930011 DOI: 10.1073/pnas.072077299  1
2002 Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZDI839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Seminars in Oncology. 29: 37-46. PMID 11894012  1
2002 Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, Schneider MD. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proceedings of the National Academy of Sciences of the United States of America. 99: 3866-71. PMID 11891332 DOI: 10.1073/pnas.062453699  1
2002 Poggioli GJ, DeBiasi RL, Bickel R, Jotte R, Spalding A, Johnson GL, Tyler KL. Reovirus-induced alterations in gene expression related to cell cycle regulation. Journal of Virology. 76: 2585-94. PMID 11861824 DOI: 10.1128/JVI.76.6.2585-2594.2002  1
2002 Johnson G. Scaffolding proteins - More than meets the eye Science. 295: 1249-1250. PMID 11847330 DOI: 10.1126/science.1069828  1
2002 Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, Tyler KL, Johnson GL. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene. 21: 260-71. PMID 11803469 DOI: 10.1038/sj.onc.1205048  1
2002 Schlesinger TK, Bonvin C, Jarpe MB, Fanger GR, Cardinaux JR, Johnson GL, Widmann C. Apoptosis stimulated by the 91-kDa caspase cleavage MEKK1 fragment requires translocation to soluble cellular compartments. The Journal of Biological Chemistry. 277: 10283-91. PMID 11782455 DOI: 10.1074/jbc.M106885200  1
2002 Bonvin C, Guillon A, van Bemmelen MX, Gerwins P, Johnson GL, Widmann C. Role of the amino-terminal domains of MEKKs in the activation of NF kappa B and MAPK pathways and in the regulation of cell proliferation and apoptosis. Cellular Signalling. 14: 123-31. PMID 11781136 DOI: 10.1016/S0898-6568(01)00219-4  1
2001 Clarke P, Meintzer SM, Widmann C, Johnson GL, Tyler KL. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun Journal of Virology. 75: 11275-11283. PMID 11689607 DOI: 10.1128/JVI.75.23.11275-11283.2001  1
2001 Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene. 20: 6910-9. PMID 11687970 DOI: 10.1038/sj.onc.1204842  1
2001 Widmann C, Sather S, Oyer R, Johnson GL, Dreskin SC. In vitro activity of MEKK2 and MEKK3 in detergents is a function of a valine to serine difference in the catalytic domain Biochimica Et Biophysica Acta - Protein Structure and Molecular Enzymology. 1547: 167-173. PMID 11343802 DOI: 10.1016/S0167-4838(01)00183-2  1
2000 Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Molecular and Cellular Biology. 20: 205-12. PMID 10594023  1
1997 Widmann C, Johnson NL, Gardner AM, Smith RJ, Johnson GL. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene. 15: 2439-47. PMID 9395240 DOI: 10.1038/sj.onc.1201421  1
1996 Vaillancourt RR, Gardner AM, Kazlauskas A, Johnson GL. The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells. Oncogene. 13: 151-9. PMID 8700541  1
1996 Gardner AM, Johnson GL. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. The Journal of Biological Chemistry. 271: 14560-6. PMID 8662985  1
1996 Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. The Journal of Biological Chemistry. 271: 3229-37. PMID 8621725 DOI: 10.1074/jbc.271.6.3229  1
1995 Winston BW, Lange-Carter CA, Gardner AM, Johnson GL, Riches DW. Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages. Proceedings of the National Academy of Sciences of the United States of America. 92: 1614-8. PMID 7878028 DOI: 10.1073/pnas.92.5.1614  1
1994 Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. The Journal of Clinical Investigation. 93: 2134-40. PMID 8182145 DOI: 10.1172/JCI117209  1
1994 Tordai A, Franklin RA, Patel H, Gardner AM, Johnson GL, Gelfand EW. Cross-linking of surface IgM stimulates the Ras/Raf-1/MEK/MAPK cascade in human B lymphocytes. The Journal of Biological Chemistry. 269: 7538-43. PMID 8125975  1
1994 Gardner AM, Vaillancourt RR, Lange-Carter CA, Johnson GL. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Molecular Biology of the Cell. 5: 193-201. PMID 8019005  1
1994 Johnson GL, Gardner AM, Lange-Carter C, Qian NX, Russell M, Winitz S. How does the G protein, Gi2, transduce mitogenic signals? Journal of Cellular Biochemistry. 54: 415-22. PMID 8014190 DOI: 10.1002/jcb.240540408  1
1994 Vaillancourt RR, Gardner AM, Johnson GL. B-Raf-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Molecular and Cellular Biology. 14: 6522-30. PMID 7935374  1
1994 Gardner AM, Lange-Carter CA, Vaillancourt RR, Johnson GL. Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Methods in Enzymology. 238: 258-70. PMID 7799792 DOI: 10.1016/0076-6879(94)38024-4  1
1993 Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. The Journal of Biological Chemistry. 268: 17896-901. PMID 8394352  1
1993 Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science (New York, N.Y.). 260: 315-9. PMID 8385802  1
1980 Kaslow HR, Johnson GL, Brothers VM, Bourne HR. A regulatory component of adenylate cyclase from human erythrocyte membranes. The Journal of Biological Chemistry. 255: 3736-41. PMID 7364766  1
1980 Johnson GL, Kaslow HR, Farfel Z, Bourne HR. Genetic analysis of hormone-sensitive adenylate cyclase. Advances in Cyclic Nucleotide Research. 13: 1-37. PMID 6251703  1
1979 Kaslow HR, Farfel Z, Johnson GL, Bourne HR. Adenylate cyclase assembled in vitro: cholera toxin substrates determine different patterns of regulation by isoproterenol and guanosine 5'-triphosphate. Molecular Pharmacology. 15: 472-83. PMID 226858  1
1979 Johnson GL, Bourne HR, Gleason MK, Coffino P, Insel PA, Melmon KL. Isolation and characterization of S49 lymphoma cells deficient in beta-adrenergic receptors: relation of receptor number to activation of adenylate cyclase. Molecular Pharmacology. 15: 16-27. PMID 34089  1
1978 Johnson GL, Kaslow HR, Bourne HR. Reconstitution of cholera toxin-activated adenylate cyclase. Proceedings of the National Academy of Sciences of the United States of America. 75: 3113-7. PMID 277913  1
1978 Johnson GL, Kaslow HR, Bourne HR. Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase. The Journal of Biological Chemistry. 253: 7120-3. PMID 212417  1
1978 Naya-Vigne J, Johnson GL, Bourne HR, Coffino P. Complementation analysis of hormone-sensitive adenylate cyclase. Nature. 272: 720-2. PMID 205796 DOI: 10.1038/272720a0  1
1977 Johnson GL, Bourne HR. Influence of cholera toxin on the regulation of adenylate cyclase by GTP. Biochemical and Biophysical Research Communications. 78: 792-8. PMID 199187 DOI: 10.1016/0006-291X(77)90249-2  1
Show low-probability matches.